SteadyMed seeks orphan drug designation from FDA for Trevyent to treat PAH
The agency has acknowledged receipt of the application and will notify the company when the review process is completed. If the FDA grants orphan drug designation, Trevyent would
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.